THE FULL STORY OF CUBA’S COVID-19 VACCINES
Posted on April 23, 2021 in Cuba, International // 0 Comments
Some 200 COVID-19 vaccines are being developed worldwide, and 23 candidates have advanced to phase III clinical trials (as of 25 March 2021). Though no other Latin American country has developed a vaccine of its own, two of the 23 now in phase III trials are Cuban: Soberana 02 and Abdala. And Cuba also has three other vaccine candidates in earlier stage trials: Soberana 01, Soberana Plus, and Mambisa. So how has Cuba managed to develop five COVID-19 vaccines in such a short time?
Cuba’s biotech sector is unique. It is entirely state-owned and free of private interests, with innovation channelled to meet public health needs and no profit-seeking in the domestic market. Dozens of research and development institutions collaborate, sharing resources and knowledge instead of competing, which facilitates a fast track from research and innovation to trials and application. Cuba has the capacity to produce 60-70% of the medicines it consumes domestically, an imperative due to the US blockade and the cost of medicines in the international market. There is also continuous and comprehensive circulation of information and personnel between universities, research centres, and the public health system. These various elements have proven vital in the development of Cuba’s COVID-19 vaccines.